Cigarette smokers who try to quit often end up vaping and smoking

Industry Insight
Jul.22.2022

Most of the 40 million Americans who smoke cigarettes say they want to quit, and some move to e-cigarettes as a step toward quitting. However, a growing number of such people become dual nicotine users: They smoke traditional cigarettes and vape e-cigarettes, researchers at Washington University School of Medicine in St. Louis have found.

Cigarette smokers who try to quit often end up vaping and smoking

Rather than discontinuing their addiction, many end up substantially increasing the amount of nicotine they consume. The good news, the researchers found, is that smoking-cessation treatments approved by the Food and Drug Administration (FDA) that focus on nicotine replacement and counseling can help such dual users quit. In fact, such treatments seem to be effective in dual users as well as those who smoke traditional cigarettes exclusively.

 

The findings are available July 21 in the journal Thorax.

 

"We recommend FDA-approved treatment such as nicotine replacement, the drug varenicline and counseling for cigarette smokers," said senior investigator Li-Shiun Chen, MD, an associate professor of psychiatry. "But we know that a growing number of people are using both cigarettes and e-cigarettes. The good news is that tobacco treatment still can help these people stop smoking and defeat their nicotine addition."

 

In an average year, about 70% of those who smoke will make an attempt to quit. Another 20% say they want to smoke less. But only about 5% of those who don't receive any treatment, such as nicotine replacement therapy and counseling, quit successfully.

 

In this review of de-identified electronic health records of more than 110,000 smokers who were seen in outpatient clinics at Barnes-Jewish Hospital between 2018 and 2020, Chen and her colleagues found that the number of e-cigarette users tripled. Some apparently started vaping as a potential step to quitting, but many seemed to get stuck. Instead of quitting, they started vaping while also continuing to smoke traditional cigarettes.

 

A relatively small but growing percentage of the smokers who were studied became dual users during the course of the study. Some 0.8% reported dual use in the study's first year, but that number had grown to 2.3% when data collection had concluded. The authors noted that the actual number of dual users was likely higher.

 

The researchers found that about one in five (20.8%) of the dual users quit smoking within 12 months. That compared to a 16.8% quit rate among those who smoked only traditional cigarettes.

 

Treatment still seemed to be the key for dual users. When they received smoking-cessation treatment, almost one-third (29%) became nonsmokers 12 months later. About 17% of dual users who didn't get treatment were able to quit.

 

First author Brendan T. Heiden, MD, a surgical resident and cardiothoracic surgery research fellow, said that although quit rates were higher among dual users, about two-thirds remained smokers a year later, even after treatment. That, combined with the fact that little is known about the long-term health effects of e-cigarette use, means that he and Chen don't recommend that people who want to quit smoking should start vaping.

 

"The current scientific consensus is that using both cigarettes and e-cigarettes is bad for you," Heiden said. "Although current guidelines do not recommend vaping for smoking cessation, we did find that among the growing number of people who use both of these products, traditional FDA-approved tobacco treatment—such as nicotine-replacement therapy and behavioral support therapy—can help them quit."

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

 

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
New Australian government estimates released on November 15, 2026, suggest that the country's illicit tobacco market may have contracted for the first time following five years of growth. Estimated market volume fell from a previous peak of 5,972 tonnes to a range of 4,453–5,893 tonnes. The government attributed the change to stronger border enforcement and coordinated domestic operations. Australian Border Force seized more than 2,300 tonnes of illicit tobacco and 13.2 million illicit vaping products in 2025–26, followed by approximately 730 tonnes of illicit tobacco in the first quarter of 2026–27. Separate experimental estimates from the Australian Bureau of Statistics indicate that illicit sources accounted for approximately 80% of nicotine consumption in 2025.
Regulations
Nov.16